Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma [Oncotarget., 9, (2018) (20323-20338)] doi 10.18632/oncotarget.24859;MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma

Oncotarget

Volumn 9, Issue 29, 2018, Pages 20323-20338

  Agarwal, Saurabh ^a   Milazzo, Giorgio ^b   Rajapakshe, Kimal ^a   Bernardi, Ronald ^a   Chen, Zaowen ^a   Barberi, Eveline ^a   Koster, Jan ^c   Perini, Giovanni ^b   Coarfa, Cristian ^a   Shohet, Jason M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

DNA damage resposone; MYCN; Neuroblastoma; P53; P53 C terminal domain

Indexed keywords

HETERODIMER; PROTEIN P53;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; CANCER RISK; CARBOXY TERMINAL SEQUENCE; CELL CYCLE PROGRESSION; CHROMATIN STRUCTURE; COHORT ANALYSIS; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION LEVEL; GENE FUNCTION; GENE INTERACTION; GENE LOCATION; GENE TARGETING; HUMAN; HUMAN CELL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MAX GENE; MYCN GENE; NEUROBLASTOMA; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE; OVERALL SURVIVAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RNA SEQUENCE; TRANSCRIPTION INITIATION;

EID: 85045528969     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.25776     Document Type: Erratum

References (52)

1. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T, Matthay KK. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011; 29:3286-92. https://doi.org/10.1200/ JCO.2010.34.3392
2. Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M, Casale F, Viscardi E, Bianchi M, D'Angelo P, Zanazzo GA, Luksch R, Favre C, et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer. 2009; 45:2835-42. https://doi.org/10.1016/j. ejca.2009.06.010
3. Kushner BH, Modak S, Kramer K, LaQuaglia MP, Yataghene K, Basu EM, Roberts SS, Cheung NK. Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era. Cancer. 2014; 120:2050-59. https://doi.org/10.1002/cncr.28687
4. Jung M, Russell AJ, Liu B, George J, Liu PY, Liu T, DeFazio A, Bowtell DD, Oberthuer A, London WB, Fletcher JI, Haber M, Norris MD, Henderson MJ. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. Cancer Res. 2017; 77:971-81. https:// doi.org/10.1158/0008-5472.CAN-15-2906
5. Vermeulen J, De Preter K, Laureys G, Speleman F, Vandesompele J. 59-gene prognostic signature sub-stratifies high-risk neuroblastoma patients. Lancet Oncol. 2009; 10:1030. https://doi.org/10.1016/S1470-2045(09)70325-0
6. Hallett RM, Seong AB, Kaplan DR, Irwin MS. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma. Mol Oncol. 2016; 10:1461-72. https://doi.org/10.1016/j. molonc.2016.07.012
7. Olsen RR, Otero JH, García-López J, Wallace K, Finkelstein D, Rehg JE, Yin Z, Wang YD, Freeman KW. MYCN induces neuroblastoma in primary neural crest cells. Oncogene. 2017; 36:5075-82. https://doi.org/10.1038/ onc.2017.128
8. Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med. 2015; 66:49-63. https://doi.org/10.1146/annurev-med-011514-023121
9. Esposito MR, Aveic S, Seydel A, Tonini GP. Neuroblastoma treatment in the post-genomic era. J Biomed Sci. 2017; 24:14. https://doi.org/10.1186/s12929-017-0319-y
10. Kim ES, Shohet JM. Reactivation of p53 via MDM2 inhibition. Cell Death Dis. 2015; 6:e1936. https://doi. org/10.1038/cddis.2015.302
11. Laptenko O, Tong DR, Manfredi J, Prives C. The Tail That Wags the Dog: How the Disordered C-Terminal Domain Controls the Transcriptional Activities of the p53 Tumor-Suppressor Protein. Trends Biochem Sci. 2016; 41:1022-34 https ://doi.org/10.1016/j.tibs.2016.08.011
12. Laptenko O, Shiff I, Freed-Pastor W, Zupnick A, Mattia M, Freulich E, Shamir I, Kadouri N, Kahan T, Manfredi J, Simon I, Prives C. The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain. Mol Cell. 2015; 57:1034-46. https://doi.org/10.1016/j.molcel.2015.02.015
13. Kim H, Kim K, Choi J, Heo K, Baek HJ, Roeder RG, An W. p53 requires an intact C-terminal domain for DNA binding and transactivation. J Mol Biol. 2012; 415:843-54. https:// doi.org/10.1016/j.jmb.2011.12.001
14. Wang D, Kon N, Lasso G, Jiang L, Leng W, Zhu WG, Qin J, Honig B, Gu W. Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode. Nature. 2016; 538:118-22. https://doi.org/10.1038/nature19759
15. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL. p53 is regulated by the lysine demethylase LSD1. Nature. 2007; 449:105-08. https://doi.org/10.1038/ nature06092
16. Amente S, Bertoni A, Morano A, Lania L, Avvedimento EV, Majello B. LSD1-mediated demethylation of histone H3 lysine 4 triggers Myc-induced transcription. Oncogene. 2010; 29:3691-702. https://doi.org/10.1038/onc.2010.120
17. Amente S, Milazzo G, Sorrentino MC, Ambrosio S, Di Palo G, Lania L, Perini G, Majello B. Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma. Oncotarget. 2015; 6:14572-83. https://doi.org/10.18632/ oncotarget.3990
18. Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S, Shohet JM. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther. 2006; 5:2358-65. https://doi.org/10.1158/1535-7163. MCT-06-0305
19. Joerger AC, Fersht AR. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol. 2010; 2:a000919. https://doi.org/10.1101/cshperspect. a000919
20. Gaglia G, Guan Y, Shah JV, Lahav G. Activation and control of p53 tetramerization in individual living cells. Proc Natl Acad Sci U S A. 2013; 110:15497-501. https:// doi.org/10.1073/pnas.1311126110
21. Gaglia G, Lahav G. Constant rate of p53 tetramerization in response to DNA damage controls the p53 response. Mol Syst Biol. 2014; 10:753. https://doi.org/10.15252/ msb.20145168
22. Petroni M, Veschi V, Gulino A, Giannini G. Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma. Front Oncol. 2012; 2:141. https://doi.org/10.3389/ fonc.2012.00141
23. Thole TM, Lodrini M, Fabian J, Wuenschel J, Pfeil S, Hielscher T, Kopp-Schneider A, Heinicke U, Fulda S, Witt O, Eggert A, Fischer M, Deubzer HE. Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. Cell Death Dis. 2017; 8:e2635. https://doi. org/10.1038/cddis.2017.49
24. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA. Super-enhancers in the control of cell identity and disease. Cell. 2013; 155:934-47. https://doi.org/10.1016/j.cell.2013.09.053
25. Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung C, Altabef A, Perez-Atayde A, Wong KK, Yuan GC, et al. CDK7 inhibition suppresses super-enhancerlinked oncogenic transcription in MYCN-driven cancer. Cell. 2014; 159:1126-39. https://doi.org/10.1016/j. cell.2014.10.024
26. Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, Barsyte-Lovejoy D, Al-awar R, Katona BW, Shilatifard A, Huang J, Hua X, Arrowsmith CH, Berger SL. Gain-offunction p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015; 525:206-11. https://doi. org/10.1038/nature15251
27. Shohet JM, Ghosh R, Coarfa C, Ludwig A, Benham AL, Chen Z, Patterson DM, Barbieri E, Mestdagh P, Sikorski DN, Milosavljevic A, Kim ES, Gunaratne PH. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer Res. 2011; 71:3841-51. https://doi. org/10.1158/0008-5472.CAN-10-4391
28. Botcheva K, McCorkle SR, McCombie WR, Dunn JJ, Anderson CW. Distinct p53 genomic binding patterns in normal and cancer-derived human cells. Cell Cycle. 2011; 10:4237-49. https://doi.org/10.4161/cc.10.24.18383
29. Koeppel M, van Heeringen SJ, Kramer D, Smeenk L, Janssen-Megens E, Hartmann M, Stunnenberg HG, Lohrum M. Crosstalk between c-Jun and TAp73alpha/beta contributes to the apoptosis-survival balance. Nucleic Acids Res. 2011; 39:6069-85. https://doi.org/10.1093/nar/gkr028
30. Aksoy O, Chicas A, Zeng T, Zhao Z, McCurrach M, Wang X, Lowe SW. The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence. Genes Dev. 2012; 26:1546-57. https://doi. org/10.1101/gad.196238.112
31. Do PM, Varanasi L, Fan S, Li C, Kubacka I, Newman V, Chauhan K, Daniels SR, Boccetta M, Garrett MR, Li R, Martinez LA. Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev. 2012; 26:830-45. https:// doi.org/10.1101/gad.181685.111
32. Smeenk L, van Heeringen SJ, Koeppel M, Gilbert B, Janssen-Megens E, Stunnenberg HG, Lohrum M. Role of p53 serine 46 in p53 target gene regulation. PLoS One. 2011; 6:e17574. https://doi.org/10.1371/journal. pone.0017574
33. Hill RM, Kuijper S, Lindsey JC, Petrie K, Schwalbe EC, Barker K, Boult JK, Williamson D, Ahmad Z, Hallsworth A, Ryan SL, Poon E, Robinson SP, et al. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell. 2015; 27:72-84. https://doi.org/10.1016/j. ccell.2014.11.002
34. Conacci-Sorrell M, McFerrin L, Eisenman RN. An overview of MYC and its interactome. Cold Spring Harb Perspect Med. 2014; 4:a014357. https://doi.org/10.1101/ cshperspect.a014357
35. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, et al, and INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009; 27:289-97. https://doi.org/10.1200/ JCO.2008.16.6785
36. Altman BJ, Hsieh AL, Sengupta A, Krishnanaiah SY, Stine ZE, Walton ZE, Gouw AM, Venkataraman A, Li B, Goraksha-Hicks P, Diskin SJ, Bellovin DI, Simon MC, et al. MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. Cell Metab. 2015; 22:1009-19. https://doi. org/10.1016/j.cmet.2015.09.003
37. Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, Metabolism, and Cancer. Cancer Discov. 2015; 5:1024-39. https://doi.org/10.1158/2159-8290.CD-15-0507
38. Carr-Wilkinson J, Griffiths R, Elston R, Gamble LD, Goranov B, Redfern CP, Lunec J, Tweddle DA. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression. Cell Cycle. 2011; 10:3778-87. https://doi. org/10.4161/cc.10.21.17973
39. Schlereth K, Heyl C, Krampitz AM, Mernberger M, Finkernagel F, Scharfe M, Jarek M, Leich E, Rosenwald A, Stiewe T. Characterization of the p53 cistrome-DNA binding cooperativity dissects p53's tumor suppressor functions. PLoS Genet. 2013; 9:e1003726. https://doi. org/10.1371/journal.pgen.1003726
40. Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 2015; 47:864-71. https://doi. org/10.1038/ng.3333
41. Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, et al. Mutational dynamics between primary and relapse neuroblastomas. Nat Genet. 2015; 47:872-77. https://doi.org/10.1038/ng.3349
42. Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb Perspect Biol. 2010; 2:a000935. https:// doi.org/10.1101/cshperspect.a000935
43. Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2017; 170:1062-78. https://doi.org/10.1016/j. cell.2017.08.028
44. Gu B, Zhu WG. Surf the post-translational modification network of p53 regulation. Int J Biol Sci. 2012; 8:672-84. https://doi.org/10.7150/ijbs.4283
45. Inoue K, Fry EA, Frazier DP. Transcription factors that interact with p53 and Mdm2. Int J Cancer. 2016; 138:1577-85 https ://doi.org/10.1002/ijc.29663
46. Grönroos E, Terentiev AA, Punga T, Ericsson J. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc Natl Acad Sci U S A. 2004; 101:12165-70. https://doi.org/10.1073/pnas.0402283101
47. Wang D, Kon N, Tavana O, Gu W. The 'readers' of unacetylated p53 represent a new class of acidic domain proteins. Nucleus. 2017; 8:360-69. https://doi.org/10.1080/19491034.2017.1313939
48. Porter JR, Fisher BE, Baranello L, Liu JC, Kambach DM, Nie Z, Koh WS, Luo J, Stommel JM, Levens D, Batchelor E. Global Inhibition with Specific Activation: How p53 and MYC Redistribute the Transcriptome in the DNA Double-Strand Break Response. Mol Cell. 2017; 67:1013-1025.e9. https://doi.org/10.1016/j.molcel.2017.07.028
49. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A. 2005; 102:731-36. https://doi.org/10.1073/ pnas.0405495102
50. Agarwal S, Ghosh R, Chen Z, Lakoma A, Gunaratne PH, Kim ES, Shohet JM. Transmembrane adaptor protein PAG1 is a novel tumor suppressor in neuroblastoma. Oncotarget. 2016; 7:24018-26. https://doi.org/10.18632/ oncotarget.8116
51. Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4:44-57. https://doi.org/10.1038/nprot.2008.211
52. Agarwal S, Lakoma A, Chen Z, Hicks J, Metelitsa LS, Kim ES, Shohet JM. G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation. Cancer Res. 2015; 75:2566-79 https ://doi.org/10.1158/0008-5472.CAN-14-2946